Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

August 30, 2016; 87 (9 Supplement 2) Article

Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders

Kevin Rostasy, Barbara Bajer-Kornek, Sunita Venkateswaran, Cheryl Hemingway, Marc Tardieu
First published August 29, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002878
Kevin Rostasy
From the Department of Pediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Germany; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Division of Neurology (S.V.), Children's Hospital of Eastern Ontario, Ottawa, Canada; Pediatric Neurology (C.H.), Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; and National Reference Center for Inflammatory Diseases of the Brain (M.T.), Hôpitaux Universitaires Paris-Sud, University Paris-Sud, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Bajer-Kornek
From the Department of Pediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Germany; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Division of Neurology (S.V.), Children's Hospital of Eastern Ontario, Ottawa, Canada; Pediatric Neurology (C.H.), Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; and National Reference Center for Inflammatory Diseases of the Brain (M.T.), Hôpitaux Universitaires Paris-Sud, University Paris-Sud, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunita Venkateswaran
From the Department of Pediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Germany; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Division of Neurology (S.V.), Children's Hospital of Eastern Ontario, Ottawa, Canada; Pediatric Neurology (C.H.), Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; and National Reference Center for Inflammatory Diseases of the Brain (M.T.), Hôpitaux Universitaires Paris-Sud, University Paris-Sud, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Hemingway
From the Department of Pediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Germany; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Division of Neurology (S.V.), Children's Hospital of Eastern Ontario, Ottawa, Canada; Pediatric Neurology (C.H.), Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; and National Reference Center for Inflammatory Diseases of the Brain (M.T.), Hôpitaux Universitaires Paris-Sud, University Paris-Sud, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Tardieu
From the Department of Pediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Germany; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Division of Neurology (S.V.), Children's Hospital of Eastern Ontario, Ottawa, Canada; Pediatric Neurology (C.H.), Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; and National Reference Center for Inflammatory Diseases of the Brain (M.T.), Hôpitaux Universitaires Paris-Sud, University Paris-Sud, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders
Kevin Rostasy, Barbara Bajer-Kornek, Sunita Venkateswaran, Cheryl Hemingway, Marc Tardieu
Neurology Aug 2016, 87 (9 Supplement 2) S28-S37; DOI: 10.1212/WNL.0000000000002878

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Comment

Downloads
1700

Share

  • Article
  • Figures & Data
  • Info
Loading

Abstract

Major advances have been made in the clinical and radiologic characterization of children presenting with the different forms of an acquired inflammatory demyelinating syndrome (ADS) such as acute disseminating encephalomyelitis, neuromyelitis optica spectrum disorders, and clinically isolated syndromes. Nevertheless, a proportion of cases that present with similar symptoms are due to a broad spectrum of other inflammatory disorders affecting the white matter, primary CNS tumors, or neurometabolic diseases. The clinician therefore has to be aware of the different forms of ADS, the risk factors for a chronic-relapsing course, and features that indicate an alternative diagnosis. The goal of this article is therefore to provide an outline of a pathway for evaluating pediatric patients with a presumed inflammatory demyelinating disorder and discussing the spectrum of the more common differential diagnoses.

GLOSSARY

ADEM=
acute disseminating encephalomyelitis;
ADS=
acquired demyelinating syndromes;
ANE=
acute necrotizing encephalopathy;
AQP4=
aquaporin-4;
BBE=
Bickerstaff brainstem encephalitis;
BBGD=
biotin-responsive basal ganglia disease;
CIS=
clinically isolated syndromes;
DIS=
dissemination in space;
DIT=
dissemination in time;
GBS=
Guillain-Barré syndrome;
HLH=
hemophagocytic lymphohistiocytosis;
IgG=
immunoglobulin G;
LCH=
Langerhans cell histiocytosis;
LETM=
longitudinally extensive transverse myelitis;
MOG=
myelin oligodendrocyte glycoprotein;
MS=
multiple sclerosis;
NMOSD=
neuromyelitis optica spectrum disorders;
ON=
optic neuritis;
PACNS=
primary angiitis of the CNS;
PCNSL=
primary CNS lymphoma;
PML=
progressive multifocal leukoencephalopathy;
SLE=
systemic lupus erythematosus;
TM=
transverse myelitis

Acquired demyelinating syndromes (ADS) represent a group of disorders such as acute disseminating encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders (NMOSD), and clinically isolated syndromes (CIS). A timely and precise diagnosis is mandatory in order to ensure adequate patient management, but due to the extensive differential diagnosis, it is not uncommon that children are assigned an incorrect diagnosis.

The focus of this review is to describe and delineate the different subtypes of ADS from the broad spectrum of other inflammatory disorders of the white matter, genetic disorders affecting the innate and adaptive immune system, primary CNS tumors, and neurometabolic diseases.

ACQUIRED DEMYELINATING SYNDROMES

The clinical picture of ADS comprises ADEM, characterized by polyfocal deficits and encephalopathy; CIS, characterized by monofocal or polyfocal deficits without encephalopathy; pediatric multiple sclerosis (MS); and NMOSD (table 1). ADS occur as a monophasic illness, but may also represent the onset of a chronic relapsing disorder.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Acute demyelinating syndromes and recommended workup

Among the various forms of ADS, ADEM offers the widest spectrum of differential diagnosis. The clinical picture of ADEM is characterized by a polyfocal onset, associated with encephalopathy.1 Encephalopathy in ADEM is defined as a qualitative or quantitative disturbance of consciousness, such as irritability, somnolence, or coma, and must occur in the absence of fever. MRI is an important tool in distinguishing ADEM from other diseases and in particular from the first attack of MS.2 Lesions found on MRI are typically diffuse, ill-defined, >1–2 cm in size, and in the cerebral white matter, but may also affect the thalamus, basal ganglia, and spinal cord. T1-hypointense lesions are rare.1 Among the patients presenting with ADS, ADEM is found more frequently in younger children.3 Typically ADEM is a monophasic disorder, but may also represent the first attack of pediatric MS.4

CIS are characterized by monofocal or polyfocal events without encephalopathy, unless explained by fever.1 The most common clinical presentations of CIS in children are optic neuritis (ON), transverse myelitis (TM), or brainstem/cerebellar syndromes or syndromes attributed to the cerebral hemispheres.3,5 Unilateral ON is defined by acute/subacute and painful visual loss, impairment of visual acuity and color perception, MRI evidence of optic nerve swelling, or abnormal signal or enhancement.3 Bilateral ON is more common in ADEM or NMOSD. TM is characterized by acute/subacute onset of bilateral symmetric or asymmetric sensory or motor deficits, sometimes associated with sphincter dysfunction, with a defined sensory level, and MRI evidence of spinal cord swelling or abnormal signal intensity or enhancement.3 If brain MRI is normal at the time of a CIS, the risk of MS is low.4 In contrast, in case of abnormal MRI studies, the distribution and morphology of lesions predicts the risk of a second clinical event with high sensitivity and specificity.6 Furthermore, the presence of oligoclonal bands in pediatric ON increases the risk of MS.7

Pediatric MS is defined by 2 or more non-ADEM episodes of presumed inflammatory demyelinating origin, separated by >30 days and involving more than one CNS site or a first nonencephalitogenic episode with an MRI fulfilling the McDonald criteria for dissemination in space (DIS) and with a follow-up MRI showing a new enhancing or nonenhancing lesion consistent with the 2010 dissemination in time (DIT) criteria. In children ≥12 years of age, a single, non-ADEM episode with MRI lesions fulfilling the 2010 McDonald criteria for DIS and DIT may also satisfy the criteria for pediatric MS. In a child with an ADEM attack that is followed by a second non-ADEM event, 3 or more months after the first episode, and new MRI lesions that fulfill the 2010 criteria for DIS and DIT, the diagnosis of pediatric MS can be assigned.1

ON or TM are the main presenting features of NMOSD.8 Other core clinical characteristics comprise an acute area postrema syndrome (intractable hiccups or vomiting), an acute brainstem syndrome, or symptomatic diencephalic (symptomatic narcolepsy) or cerebral syndrome with NMOSD-typical MRI lesions in conjunction with aquaporin-4 (AQP4) antibodies.9 While many clinical, imaging, and CSF features are similar to those found in adult NMOSD, some caveats remain. In particular, longitudinally extensive transverse myelitis (LETM) may be less specific for pediatric NMO, since LETM also may be found in pediatric MS, as well as in monophasic ADEM.9,10 Recently, pediatric cases with the clinical picture of ADEM, accompanied by the presence of AQP4 antibodies, also have been described.11

Among children with ADS, a subgroup of patients shows serologic evidence for myelin oligodendrocyte glycoprotein (MOG) antibodies. Children with MOG-associated demyelinating CNS disease may present with various clinical features, including ADEM, ADEM followed by ON, or NMOSD.9,12,13 MOG-associated ADEM in children shows a uniform radiologic pattern with large, hazy lesions, the absence of abnormal MRI features, and involvement of more CNS areas including spine LETM.9

Recent studies showed that the presence of MOG antibodies argues against a further diagnosis of MS.14 However, the long-term evolution of children with MOG antibodies needs further prospective evaluation.

RED FLAGS SUGGESTING AN ALTERNATIVE DIAGNOSIS IN CHILDREN WITH ADS

In children with an acute demyelinating event, the following red flags should challenge the diagnosis of ADS: onset before age 1 year; history of developmental delay; consanguineous family; family history of severe, acute neurologic symptoms; gradual progression of symptoms; and multisystemic involvement (table 2). Unusual MRI features that are infrequent in ADS are a single supratentorial white matter lesion, symmetric white matter involvement, or lesions restricted solely to the brainstem and basal ganglia (table 3).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2

Clinical red flags for conditions other than acquired demyelinating syndromes

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3

Imaging features such as preferred location and additional features of disorders other than acquired demyelinating syndromes

INFLAMMATORY DISEASES OF THE WHITE MATTER OTHER THAN ADS

CNS vasculitis.

CNS vasculitis is one of the most challenging differential diagnoses of ADS and is divided into secondary forms, which are part of a systemic disease or primary angiitis of the CNS (PACNS) (table 4).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 4

Selected diseases mimicking an acute demyelinating syndrome with clinical clues and recommended workup that should be tailored according to clinical symptoms and likelihood of an alternative diagnosis

Presenting symptoms are often nonspecific, with headache, confusional state, or behavioral alteration reminiscent of psychosis, depression, cognitive decline, seizures, or focal neurologic signs. Although imaging findings in CNS vasculitis can be indistinguishable from various forms of ADS (e.g., TM, MS), several findings are characteristic for CNS vasculitis, such as leptomeningeal and vessel wall enhancement, in combination with atrophic areas suggestive of previous events (figure, E).15 MRI and even conventional angiography can be normal despite neuropathologic evidence of CNS vasculitis.15 Diagnosis may need to be confirmed by brain biopsy.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Cerebral and spinal MRI of children with episodes of an acquired demyelinating syndrome and examples of diseases than can initially present with similar symptoms

(A) MRI of a 7-year-old girl with a fulminant episode of acute disseminating encephalomyelitis (ADEM) characterized by encephalopathy, respiratory distress, focal neurologic signs, and myelin oligodendrocyte glycoprotein antibodies shows hazy bilateral and large signal intensities in the subcortical white matter. (B) Cerebral MRI of a 15-year-old girl who developed an acute hemorrhagic leukoencephalopathy after a urinary infection with Escherichia coli. (C) MRI of a 4-year-old boy with sudden onset of ataxia and drowsiness shows multiple subcortical white matter lesions reminiscent of ADEM. The patient was diagnosed with an X-linked immunoproliferative disease due to a mutation in the SH2 domain protein 1A. (D) Cerebral MRI of a 10-year-old boy who presented with irritability, vomiting, double vision, and vertigo shows hazy bilateral lesions in the white matter and thalami. A high titer of aquaporin-4 antibodies was detected and he was diagnosed with neuromyelitis optica spectrum disorder. (E) A 12-year-old girl with episodes of impaired unilateral vision and hemiparesis initially diagnosed with multiple sclerosis had multiple small white matter lesions on the left side of her brain. Magnetic resonance angiography and CSF pleocytosis pointed to the diagnosis of CNS vasculitis. After further stroke-like episodes, she was started on cyclophosphamide, leading to significant improvement. (F) A 13-year-old boy presented with bilateral motor weakness, ataxia, and unilateral peripheral facial nerve palsy. His initial MRI with large bilateral lesions also affecting the corpus callosum pointed to a multifocal clinically isolated syndrome. Subsequent neurophysiologic studies and response to IV immunoglobulin confirmed the diagnosis of Guillain-Barré syndrome with white matter lesions. (G) A 13-year-old girl presented with nausea, vomiting, and loss of consciousness due to a prominent cerebellitis affecting white matter and cortical structures of the cerebellum. (H) A 16-year-old boy was admitted with weakness in both arms, which had gradually evolved during the last 3 weeks. MRI of the spine reveals an edematous swelling of the myelin extending more than 3 segments. CSF studies and serologic studies showed immunoglobulin M and an intrathecal synthesis of immunoglobulin G antibodies against Borrelia burgdorferi. (I) A 4-year-old girl developed somnolence, motor weakness, and gait ataxia after a viral infection. Her MRI shows symmetric lesions in the midbrain extending into the basal ganglia suggestive of acute necrotizing encephalitis. She had a mild CSF pleocytosis and a good response to IV steroids. Further workup revealed a mutation in the RANBP2 gene.

Systemic lupus erythematosus (SLE).

General symptoms of SLE include a malar rash, arthritis, and fever. Neurologic and psychiatric symptoms often develop during the course of the disease but can also be the first signs of the disease.16 The diagnosis is established considering the involvement of different organ systems in combination with anemia, thrombocytopenia, and the presence of antibodies to double-stranded DNA, or high antiphospholipid antibodies. Few studies exist describing the MRI findings in children with SLE, which can include nonspecific T2 signal alterations in particular at the beginning of the disease, larger areas of demyelination, and TM in addition to cortical and subcortical strokes.16,17

Behçet disease.

Behçet disease is a systemic disorder with neurologic symptoms in 20% of pediatric cases.18 The neurologic presentations can be variable and the sole presenting sign of the disease. The neurologic manifestations are often linked to high intracranial pressure due to cerebral venous sinus thrombosis, inflammation of the white matter, or stroke due to vasculitis. The course of the disease is relapsing, sometimes despite treatment. Cerebral MRI can demonstrate venous sinus thrombosis and less often white matter lesions reminiscent of MS, which is more common in adults.18 CSF studies are normal in up to 50% of cases.

Primary angiitis of the CNS.

The diagnosis of PACNS is based on 3 criteria: (1) an acquired neurologic deficit, (2) angiographic or histologic evidence of cerebral vasculitis, and (3) absence of systemic vasculitis.19 PACNS affects the medium-sized and small vessels and remains a rare and difficult diagnosis. Clinical presentations in small vessel disease include seizures, headache, and cognitive decline but also ON or TM.19 In children with small vessel disease, systemic signs of inflammation are often present, such as an elevated erythrocyte sedimentation rate, chronic reactive protein, or von Willebrand factor, which has been suggested as a clinical marker of disease activity.20 CSF studies often reveal an elevated opening pressure, pleocytosis, and increased protein levels.21 MRI may demonstrate white matter lesions reminiscent of ADS and normal magnetic resonance angiography. A definitive diagnosis requires brain biopsy encompassing the meninges, gray matter, and white matter, ideally prior to initiation of glucocorticoid treatment.15 Medium-sized vessel disease usually presents with a stroke or TIA.

Neurosarcoidosis.

Granulomatous disorders such as sarcoidosis are often included in the differential diagnosis of ADS. Although selected cases have been described, children rarely present with sole neurologic symptoms such as aseptic meningitis, cranial neuropathy, or space-occupying lesions. Most children have systemic symptoms at initial presentation such as arthritis or swelling of the parotid gland.22 In CSF, elevated opening pressure, lymphocytosis, and elevated protein are common. Brain MRI can demonstrate granulomata in the parenchyma, frequently enhancing after gadolinium administration and periventricular white matter lesions. A lesional biopsy may be required to establish the diagnosis.

Genetic defects affecting the immune response.

Hemophagocytic lymphohistiocytosis (HLH) represents a group of inherited immunodeficiencies, including familial HLH, Griscelli syndrome type 2, and X-linked lymphoproliferative syndrome, which are caused by defects in natural killer cells and CD8 T-cell cytotoxicity. Secondary forms are found in combination with infections, cancer, and other autoimmune disorders.23 Primary HLH remains asymptomatic until a viral infection, such as Epstein-Barr virus, triggers the activation of CD8+ T lymphocytes and macrophages. Initial symptoms can be restricted to the CNS and consist of seizures, impaired consciousness, meningism, and focal motor deficits.24 Biological markers indicating HLH are pancytopenia, low fibrinogen levels, and elevated liver enzyme and ferritin levels. Signs of hemophagocytosis are detectable on CSF/blood/bone marrow smears in two-thirds of children. CSF results can be abnormal in half of all children demonstrating high protein and increased cell count.25 Cerebral MRI can demonstrate symmetric white matter lesions sometimes difficult to differentiate from ADEM in addition to signal hypointensity on T1 sequences (figure, C, table 4).

Infections.

Neuroborreliosis.

In general, children with Lyme neuroborreliosis present with unilateral or bilateral 7th nerve palsy or meningitis. Most cases occur in the late spring and summer and in the 5- to 14-year age group with neurologic involvement in 5%–15% of children.26 Diagnosis relies on the presence of a CSF pleocytosis and an intrathecal synthesis of immunoglobulin G (IgG) and immunoglobulin M antibodies against the pathogen. Infections with Borrelia burgdorferi affecting the neuroaxis can present as ON or TM with or without radiologic evidence of LETM (figure, H) or CNS vasculitis with white matter lesions and focal neurologic signs.27

Progressive multifocal leukoencephalopathy (PML).

JC virus is a ubiquitous polyomavirus that causes PML, a frequently fatal demyelinating disease, in particular in immunocompromised patients. Presentation can be insidious with cognitive decline or more rapid with seizures and gait abnormalities. MRI changes show T2-hyperintense lesions in the frontoparietal white matter. Contrast enhancement is unusual. Diagnosis is confirmed on finding JC virus DNA in the CSF.28

Autoantibody-mediated diseases associated with white matter changes.

Several antibodies against neuronal surface antigens have been detected in recent years. Although they commonly present with encephalitis, psychiatric symptoms, refractory seizures, or movement disorders, some of them have been shown to be associated with white matter lesions on MRI. Glycine receptor antibodies usually observed in stiff-person syndrome have been found in children and adults with ON.29 CSF antibodies to the inhibitory γ-aminobutyric acid A receptor have been discovered in children with encephalitis and white matter changes.30 Titulaer et al.31 recently reported adults with NMDA receptor encephalitis who subsequently developed demyelinating syndromes associated with MOG or AQP4 antibodies.

Steroid-responsive encephalopathy is characterized by the combination of anti–thyroperoxidase antibodies with symptoms such as acute encephalitis with seizures, focal neurologic signs, and neuropsychiatric symptoms. Brain MRI lesions can involve the white and gray matter in particular of the subcortical regions and brainstem, often in a symmetrical fashion, which are distinct from MS or ADEM in most cases.32

Acute inflammatory episodes with demyelination other than ADS.

Acute cerebellitis is defined by symptoms and MRI changes related primarily to the cerebellum and signs of inflammation in the CSF such as an elevated CSF cell count. Acute cerebellitis can lead to severe brainstem dysfunction. In less acute forms, unilateral or bilateral signal changes of the cerebellar cortex around the dentate nucleus or white matter are observed (figure, G). In children in whom the MRI additionally demonstrates supratentorial, brainstem, or spinal lesions, an inflammatory process such as ADEM should be considered.

Miller Fisher syndrome, Guillain-Barré syndrome (GBS), and Bickerstaff brainstem encephalitis (BBE) have been considered part of a clinical spectrum with a range of symptoms involving the CNS and peripheral nervous system. BBE reflecting the severe end of the spectrum is characterized by encephalopathy and signs of brainstem dysfunction in addition to hyporeflexia or areflexia.33 CSF shows a normal cell count but an elevated protein. Increased titers of anti-GQ1b-IgG antibodies can be used in support of diagnosis. White matter lesions affecting the brainstem or other regions have been reported in up to 1/3 of patients with GBS and BBE (figure, F). Timely diagnosis is important because of the severity and usually prompt response to immunotherapy.33

TUMORS

Solid tumors of the CNS.

Tumors such as oligodendroglioma, ependymoma, low-grade astrocytoma, and high-grade glioma may initially lead to the incorrect diagnosis of ADS. Important signs are a gradual development of clinical symptoms, the absence of multiple lesions on initial MRI, and lesions that also involve cortical areas extending to other anatomical areas. Disseminated astrocytoma can have spatial dissemination. CSF cell count can be elevated in addition to a high protein. It is recommended to always include a cytospin CSF analysis in the workup of a child with an unusual clinical presentation and inconclusive MRI findings.

Primary CNS lymphoma (PCNSL).

PCNSL is often included in the differential diagnosis of an acute demyelinating event. PCNSL is an exceedingly rare but challenging diagnosis in children. Localization of PCNSL is often in the cerebral hemispheres but can be at any anatomical site including the leptomeninges. Therefore, symptoms at presentation are highly variable, including headache, visual problems, ataxia, seizures, and hemiparesis. MRI often reveals lesions in the cerebral hemispheres, basal ganglia, cerebellum, or brainstem, occasionally with meningeal enhancement.34 Diagnosis is confirmed by brain biopsy or immunophenotypic analyses of CSF. The majority of children reported in the literature have a CNS non-Hodgkin lymphoma.34

Langerhans cell histiocytosis (LCH).

LCH is a multisystem disease and neurologic symptoms are primarily related to solitary or multifocal lesions in meninges and other areas of the CNS including the brainstem and cerebellum.35 In the absence of a clinical history of LCH, an isolated CNS lesion presents a diagnostic challenge. MRI findings in these patients include symmetric hyperintense signals in T1-weighted images in the cerebellar gray and white matter, cerebellar atrophy, T2-weighted hyperintense changes in the pons, and T1-weighted hyperintensity of the globus pallidum.

NEUROMETABOLIC DISEASES

A range of neurometabolic conditions are associated with white matter changes in the CNS, many of which present acutely in the context of a nonspecific illness with encephalopathy and neurologic symptoms, reminiscent of ADEM. MRI changes that are symmetrical and involve the striatum should alert the clinician to investigate in particular treatable diseases such as biotin-responsive basal ganglia disease (table 4).

Mitochondrial respiratory chain defects can present with symptoms and MRI findings indistinguishable from ADS. An evaluation of lactate content and of lactate/pyruvate ratio in blood and CSF, spectroscopy focusing on white matter lesions, and a direct study of respiratory chain activity in fibroblasts or muscle biopsy may be required in addition to genetic testing to establish the diagnosis. Leber hereditary optic neuropathy, caused by point mutations in mtDNA, deserves special consideration because of its associations with MS and ON.36,37 Other important mitochondrial disorders include Leigh syndrome, Kearns-Sayre syndrome, or leukoencephalopathy with brainstem and spinal cord involvement.38 The latter disease can present in a previously healthy child with pyramidal and cerebellar dysfunction. MRI abnormalities include spotty, periventricular white matter changes, as well as cerebellar white matter, brainstem, and spinal cord imaging similar to LETM. Further episodes can occur and respond to steroids.38

Two other diseases affecting cellular energy metabolism are biotin-responsive basal ganglia disease (BBGD), which is due to a SLC19A3 mutation, and acute necrotizing encephalopathy (ANE). In the latter, a heterozygous mutation in RANBP2 is found in familial and recurrent ANE, a rapidly progressive encephalopathy that typically occurs in previously healthy children between 6 and 18 months of age.39 Typically, there is a prodrome of a febrile illness prior to the acute phase of encephalopathy with loss of consciousness and seizures. Mortality and neurologic sequelae are common in particular in cases not treated promptly with steroids (figure, I). Liver transaminases are mildly elevated with increased CSF protein in the absence of pleocytosis. MRI demonstrates symmetrical involvement of the thalamus, with additional regions affected including the periventricular white matter, putamen, internal capsule, brainstem, and cerebellum.39

BBGD should be considered in the context of an ADEM-like presentation and symmetrical basal ganglia involvement and treated immediately with biotin and thiamin.

Leukodystrophies such as Alexander disease, X-linked adrenoleukodystrophy, or metachromatic leukodystrophy can present at various ages with atypical presentations and MRIs, but due to their progressive nature and MRI patterns, should be differentiated easily from acute demyelinating syndromes.

MIGRAINE

The detection of nonspecific incidental white matter changes in children with headache, or more specifically migraine, is now well-established. Different series demonstrate a similar rate of up to 6% of white matter hyperintensities with a trend for a higher prevalence in migraine with aura.40 Lesions are only supratentorial. The distinction from CIS is usually on clinical grounds and on differences in signal intensity, localization, and absence of gadolinium enhancement.

DISCUSSION

Precise and detailed description of the clinical picture, along with MRI and CSF studies, allow the characterization of the different ADS in the majority of children. Nevertheless, a proportion of cases are due to a broad spectrum of other inflammatory disorders of the white matter, primary CNS tumors, and neurometabolic diseases. The clinician therefore has to be aware of the different forms of ADS, the risk factors for a chronic-relapsing course, and features that indicate an alternative diagnosis.

AUTHOR CONTRIBUTIONS

Kevin Rostasy: concept, outline, and writing of the manuscript. Barbara Bajer-Kornek: writing of the manuscript. Sunita Venkateswaran: writing of the manuscript and tables. Cheryl Hemingway: writing of the manuscript. Marc Tardieu: concept, outline, and writing of the manuscript. All authors contributed extensively to the editing and consensus-finding process of all sections of the manuscript.

STUDY FUNDING

This supplement is made possible by funding from the MS Cure Fund, Danish MS Society, German MS Society, Italian MS Association, MS International Federation, MS Research Foundation (Netherlands), National MS Society (USA) and Swiss MS Society.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Received August 19, 2015.
  • Accepted in final form February 4, 2016.
  • © 2016 American Academy of Neurology

REFERENCES

  1. 1.↵
    1. Krupp LB,
    2. Tardieu M,
    3. Amato MP, et al.
    International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013;19:1261–1267.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Ketelslegers IA,
    2. Neuteboom RF,
    3. Boon M,
    4. Catsman-Berrevoets CE,
    5. Hintzen RQ
    ; Dutch Pediatric MS Study Group. A comparison of MRI criteria for diagnosing ADEM and MS. Neurology 2010;74:1412–1415.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Banwell B,
    2. Kennedy J,
    3. Sadovnick D, et al.
    Incidence of acquired demyelination of the CNS in children. Neurology 2009;72:232–239.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Verhey LH,
    2. Branson HM,
    3. Shroff MM, et al.
    Canadian Pediatric Demyelinating Disease Network. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011;10:1065–1073.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Ketelslegers IA,
    2. Catsman-Berrevoets CE,
    3. Neuteboom RF, et al.
    Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide survey. J Neurol 2012;259:1929–1935.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Kornek B,
    2. Schmitl B,
    3. Vass K, et al.
    Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome. Mult Scler 2012;18:1768–1774.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Heussinger N,
    2. Kontopantelis E,
    3. Gburek-Augustat J, et al.
    Oligoclonal bands predict multiple sclerosis in children with optic neuritis. Ann Neurol 2015;77:1076–1082.
    OpenUrlPubMed
  8. 8.↵
    1. Wingerchuk DM,
    2. Banwell B,
    3. Bennett JL, et al.
    International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–189.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Baumann M,
    2. Sahin K,
    3. Lechner C, et al.
    Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265–272.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Verhey LH,
    2. Branson HM,
    3. Makhija M,
    4. Shroff M,
    5. Banwell B
    . Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology 2010;52:1153–1162.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Absoud M,
    2. Lim MJ,
    3. Appleton R, et al.
    Paediatric neuromyelitis optica: clinical, MRI of the brain and prognosis. J Neurol Neurosurg Psychiatry 2015;86: 470–472.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Huppke P,
    2. Rostasy K,
    3. Karenfort M, et al.
    Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013;19:941–946.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Rostasy K,
    2. Mader S,
    3. Hennes E, et al.
    Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Arch Neurol 2012;69:752–756.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ketelslegers IA,
    2. Van Pelt DE,
    3. Bryde S, et al.
    Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 2015;21:1513–1520.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Twilt M,
    2. Benseler SM
    . CNS vasculitis in children. Mult Scler Relat Disord 2013;2:162–171.
    OpenUrlPubMed
  16. 16.↵
    1. Muscal E,
    2. Robin L,
    3. Brey RL
    . Neurological manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 2010;28:61–73.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Benseler SM,
    2. Silverman ED
    . Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007;16:564–571.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Uluduz D,
    2. Kurtuncu M,
    3. Yapici Z, et al.
    Clinical characteristics of pediatric onset neuro-Behçet disease. Neurology 2011;77:1900–1905.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Elbers J,
    2. Halliday W,
    3. Hawkins C, et al.
    Brain biopsy in children with primary small-vessel central nervous system vasculitis. Ann Neurol 2010;68:602–610.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Cellucci T,
    2. Tyrrell PN,
    3. Pullenayegum E,
    4. Benseler SM
    . Von Willebrand factor antigen: a possible biomarker of disease activity in childhood central nervous system vasculitis? Rheumatology 2012;51:1838–1845.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Hutchinson C,
    2. Elbers J,
    3. Halliday W, et al.
    Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study. Lancet Neurol 2010;9:1078–1084.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Anand G,
    2. Sin FE,
    3. Soilleux E, et al.
    Isolated paediatric neurosarcoidosis presenting as epilepsia partialis continua: a case report and review of the literature. Eur J Paediatr Neurol 2013;17:429–436.
    OpenUrlPubMed
  23. 23.↵
    1. Horne A,
    2. Trottestam H,
    3. Arico M, et al.
    Histiocyte Society. Frequency and spectrum of central nervous system involvement in 193 children with hemophagocytic lymphohistiocytosis. Br J Haematol 2008;140:327–335.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Deiva K,
    2. Mahlaoui N,
    3. Beaudonnet F, et al.
    CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology 2012;78:1150–1156.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Mahlaoui N,
    2. Ouachée-Chardin M,
    3. de Saint Basile G, et al.
    Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 2007;120:e622–e628.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. O'Connell S
    . Lyme borreliosis: current issues in diagnosis and management. Curr Opin Infect Dis 2010;23:231–235.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Baumann M,
    2. Birnbacher R,
    3. Koch J,
    4. Strobl R,
    5. Rostásy K
    . Uncommon manifestations of neuroborreliosis in children. Eur J Paediatr Neurol 2010;14:274–277.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Ferenczy MW,
    2. Marshall LJ,
    3. Nelson CD, et al.
    Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012;25:471–506.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Martinez-Hernandez E,
    2. Sepulveda M,
    3. Rostásy K, et al.
    Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol 2015;72:187–193.
    OpenUrlPubMed
  30. 30.↵
    1. Petit-Pedrol M,
    2. Armangue T,
    3. Peng X, et al.
    Encephalitis with refractory seizures, status-epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen and analysis of the effects of antibodies. Lancet Neurol 2014;13:276–286.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Titulaer MJ,
    2. Hoftberger R,
    3. Iizuka T, et al.
    Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;75:411–428.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Mamoudjy N,
    2. Korff C,
    3. Maurey H, et al.
    Hashimoto's encephalopathy: identification and long-term outcome in children. Eur J Paediatr Neurol 2013;17:280–287.
    OpenUrlPubMed
  33. 33.↵
    1. Pavone P,
    2. Le Pira A,
    3. Greco F, et al.
    Bickerstaff's brainstem encephalitis (BBE) in childhood: rapid resolution after intravenous immunoglobulins treatment. Eur Rev Med Pharmacol Sci 2014;18:2496–2499.
    OpenUrlPubMed
  34. 34.↵
    1. Abla O,
    2. Weitzman S,
    3. Blay JY, et al.
    Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res 2011;17:346–352.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Savardekar A,
    2. Tripathi M,
    3. Bansal D,
    4. Vaiphei K,
    5. Gupta SK
    . Isolated tumorous Langerhans cell histiocytosis of the brainstem: a diagnostic and therapeutic challenge. J Neurosurg Pediatr 2013;12:258–261.
    OpenUrlPubMed
  36. 36.↵
    1. Palace J
    . Multiple sclerosis associated with Leber's hereditary optic neuropathy. J Neurol Sci 2009;286:24–27.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Weisfeld-Adams JD,
    2. Katz Sand IB,
    3. Honce JM, et al.
    Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain 2015;138:517–539.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Wolf N,
    2. Toro C,
    3. Kister I, et al.
    DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder. Neurology 2015;84:226–230.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Neilson DE,
    2. Adams MD,
    3. Orr CM, et al.
    Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet 2009;84:44–51.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Candee MS,
    2. McCandless RT,
    3. Moore KR, et al.
    White matter lesions in children and adolescents with migraine. Pediatr Neurol 2013;49:393–396.
    OpenUrlPubMed
View Abstract

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • ACQUIRED DEMYELINATING SYNDROMES
    • RED FLAGS SUGGESTING AN ALTERNATIVE DIAGNOSIS IN CHILDREN WITH ADS
    • INFLAMMATORY DISEASES OF THE WHITE MATTER OTHER THAN ADS
    • TUMORS
    • NEUROMETABOLIC DISEASES
    • MIGRAINE
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info

Related Articles

  • No related articles found.

Topics Discussed

  • Multiple sclerosis
  • Acute disseminated encephalomyelitis

Alert Me

  • Alert me when this article is cited
  • Alert me if a correction is posted
  • Alert me when eletters are published
Advertisement
Neurology: 92 (7)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2019 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise